Atossa Therapeutics (ATOS) Income from Discontinued Operations (2015)
Atossa Therapeutics' (ATOS) quarterly Income from Discontinued Operations came in at -$2.4 million in Q4 2015, down 335.35% quarter-over-quarter from -$544802.0 in Q3 2015.
Powered by 
Analysis
Atossa Therapeutics (ATOS) Income from Discontinued Operations (2015) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Income from Discontinued Operations for 1 consecutive years, with -$2.4 million the latest figure, recorded in Q4 2015.
- On a quarterly basis, Income from Discontinued Operations changed N/A year-over-year to -$2.4 million in Q4 2015; TTM through Sep 2016 was -$2.4 million, a N/A change from a year earlier, with the FY2015 full-year figure at -$3.0 million, down 20.71% from the prior year.
- Income from Discontinued Operations was -$2.4 million for Q4 2015 at Atossa Therapeutics, down from -$544802.0 in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at -$23438.0 in Q2 2015 and troughed at -$2.4 million in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | - |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 8.00 Mn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | - |
| 10 | Atossa Therapeutics | 25.15 Mn | 25.15 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2015 | -2.37 Mn |
| Sep 30, 2015 | -544,802.00 |
| Jun 30, 2015 | -23,438.00 |
| Mar 31, 2015 | -61,204.00 |